Sep 08, 2025
BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting
Sep 06, 2025
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
Aug 27, 2025
BioMarin to Participate in Upcoming Investor Conferences
Aug 04, 2025
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS
Jul 22, 2025
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET
Jul 01, 2025
BioMarin Announces Completion of Acquisition of Inozyme
Jun 24, 2025
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
May 16, 2025
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
May 12, 2025
BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings
May 01, 2025
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance
Apr 02, 2025
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
Feb 24, 2025
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
Feb 19, 2025
BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance
Feb 05, 2025
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET
Jan 13, 2025
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court
Jan 06, 2025
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA
Nov 16, 2024
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
Oct 29, 2024
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
Sep 04, 2024
BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
Sep 04, 2024
BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time